The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.z

Path: Obliterative (constrictive) bronchiolitis (see also IVc, IVn)

Publications

Bruguera-Àvila N, Sánchez-Martínez E, Garcia-Olivé I, Pérez-Ochoa JF, Martínez-Barenys C, Ruiz-Manzano J

Obliterating bronchiolitis in a patient treated with (D)-penicillamine.

Archivos de bronconeumologia. 2013;49(9):411-2

Boehler A, Vogt P, Speich R, Weder W, Russi EW

Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine.

The European respiratory journal. 1996;9(6):1317-9

Epler GR, Snider GL, Gaensler EA, Cathcart ES, FitzGerald MX, Carrington CB

Bronchiolitis and bronchitis in connective tissue disease. A possible relationship to the use of penicillamine.

JAMA. 1979;242(6):528-32